Johnson & Johnson has offered up to $5.5bn to resolve years-long litigation regarding claims that its talc-based baby powder products cause cancer, aiming to close a complex legal battle that led the company to halt sales of the products.
Johnson & Johnson has advanced a proposal to pay $5.5bn to settle a massive wave of baby powder lawsuits, according to BBC News reporting from July 2026. The proposed settlement targets a protracted legal battle over allegations that the company’s talc products cause cancer, marking a notable financial move in the pharmaceutical giant’s ongoing efforts to resolve nationwide litigation.
Litigation History and Sales Phase-Out
The legal challenges stem from lawsuits alleging that Johnson & Johnson’s talcum powder caused users to develop ovarian cancer through feminine hygiene use, or mesothelioma affecting the lungs and other organs, as reported by KERO 23 ABC News Bakersfield. These claims heavily impacted market demand, contributing to a drop in baby powder sales that prompted the company to stop selling talc-based products in the United States in 2020. By 2022, Johnson & Johnson announced plans to cease sales of the product worldwide.
Despite offering billions to settle the disputes, the company has consistently maintained its position on product safety. According to KERO 23 ABC News Bakersfield, Johnson & Johnson continues to stand by the safety of its products and reiterated that none of the talc-related claims against it have merit.
Restructuring Proposals and Settlement Scope
The current legal maneuvering follows earlier attempts by a subsidiary of Johnson & Johnson to resolve the claims through bankruptcy proceedings. In May 2024, a J&J subsidiary proposed paying approximately $6.48 billion over 25 years to cover U.S. ovarian cancer talc allegations. That earlier plan encountered different voting frameworks; however, the company subsequently noted that its reorganization strategies included specific provisions such as a three-month solicitation period allowing ovarian claimants to vote on the plan, requiring a 75% approval threshold to proceed with a prepackaged Chapter 11 bankruptcy confirmation.
According to previous company disclosures covered by KERO 23 ABC News Bakersfield, comprehensive resolution plans were designed to address the vast majority of pending talc litigation in the United States. While personal injury lawsuits related to mesothelioma, state consumer protection claims, and claims against talc suppliers have been handled through separate agreements outside core bankruptcy plans, the overarching settlement structures reflect an ongoing corporate strategy to eliminate thousands of outstanding individual actions.
Market Repercussions and Next Legal Steps
Financial markets have frequently responded to developments in the talc litigation landscape. When previous multi-billion-dollar settlement proposals were announced, company shares rose more than 2% before the market open, illustrating how closely investors monitor the removal of legal overhangs from Johnson & Johnson’s balance sheet.
As the legal process moves forward in 2026, the $5.5bn proposal reported by BBC News highlights the immense financial cost required to address decades of consumer claims. Whether courts and claimants will accept this latest financial offer remains the central question determining the final closure of one of the largest product liability battles in corporate history.
Related reading
